Abstract
Background: Glucose dehydrogenases have been highly promoted to high-accuracy blood glucose (BG) monitors. The flavin adenine dinucleotide glucose dehydrogenase (FAD-GDH) and mutant variant of quinoprotein glucose dehydrogenase (Mut. Q-GDH) are widely used in high-performance BG monitors for multi-patient use. Therefore we conducted accuracy evaluation of the GDH monitors, FAD-GDH-based GM700 and Mut. Q-GDH-based Performa. Methods: Different patients were enrolled: patients with and without diabetes, patients receiving respiratory therapies, hemodialysis (HD) and peritoneal dialysis (PD) patients, and neonates. The accuracy evaluation of FAD-GDH- and Mut. Q-GDH-based monitors referred to ISO 15197:2013 which applies new criteria for the minion accuracy requirements: more than 95% of the blood glucose readings shall fall within ±. 15. mg/dL of the reference method at glucose concentration
Original language | English |
---|---|
Pages (from-to) | 28-33 |
Number of pages | 6 |
Journal | Clinica Chimica Acta |
Volume | 433 |
DOIs | |
Publication status | Published - Jun 10 2014 |
Keywords
- Arterial blood
- Blood glucose monitoring system
- Glucose dehydrogenase
- Hemodialysis
- ISO 15197:2013
- Neonate
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Biochemistry, medical
- Medicine(all)